Thalidomide-5-propargyl
Thalidomide-5-propargyl is a functionalized thalidomide derivative optimized for use as an E3 ligase ligand in PROTAC (Proteolysis Targeting Chimera) and molecular glue studies. Featuring a propargyl group at the 5-position, this compound enables straightforward conjugation to various linkers or target-binding moieties through click chemistry or other coupling methods. As a ligand for the cereblon (CRBN) E3 ubiquitin ligase, Thalidomide-5-propargyl plays a crucial role in recruiting CRBN to drive selective ubiquitination and proteasomal degradation of target proteins. This versatile reagent supports the rational design and synthesis of next-generation targeted protein degradation therapeutics and research tools.
Structure of 2226303-74-6
Assurance
Delivery
Support
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
- Comprehensive PROTAC Platform
- Scientific Expertise & Technical Support
- Custom Synthesis & Design Service
- Extensive Product Coverage
- Cutting-Edge Innovation
- Fast Delivery & Global Support
- 24/7 customer service
- 100% quality assurance
Popular Publications Citing BOC Sciences Products
Background Introduction
Thalidomide-5-propargyl is a chemically modified analog of the classic immunomodulatory drug thalidomide, specifically substituted at the 5-position with a propargyl group. This structural modification provides an alkyne functional handle, broadening its versatility for click chemistry and conjugation reactions. As a key ligand for Cereblon (CRBN), an E3 ubiquitin ligase substrate-recognition subunit, thalidomide-5-propargyl plays a vital role in targeted protein degradation (TPD) platforms, most notably in the design and synthesis of CRBN-recruiting PROTACs (Proteolysis Targeting Chimeras).
Mechanism
Thalidomide-5-propargyl specifically binds to the CRBN protein, a core component of the CUL4-CRBN E3 ubiquitin ligase complex. Upon incorporation into a bifunctional molecule (such as a PROTAC), thalidomide-5-propargyl facilitates the recruitment of CRBN to the target protein of interest, driving polyubiquitination and proteasomal degradation. The propargyl (alkyne) group at the 5-position offers a highly reactive site for copper-catalyzed azide-alkyne cycloaddition (CuAAC, or 'click chemistry'), enabling efficient linker attachment and flexible molecular assembly during PROTAC construction.
Applications
Thalidomide-5-propargyl is widely used as a key building block in the synthesis of CRBN-based PROTACs and molecular glue degraders. Its alkyne functionality is ideal for modular click chemistry approaches, expediting SAR studies and enabling rapid analogue synthesis. Key applications include:
• Construction of CRBN-recruiting linkers for PROTAC and heterobifunctional degrader design• Development of click chemistry-enabled libraries for medicinal chemistry optimization
• Generation of custom protein degraders for drug discovery and mechanistic biology research
• Facilitating site-specific bioconjugation strategies in both academic and pharmaceutical environments
By leveraging its unique chemistry, thalidomide-5-propargyl greatly enhances flexibility and efficiency in next-generation targeted protein degradation research.
• Consistent batch-to-batch reproducibility with complete QC documentation
• Supplied with COA, MSDS, and analytical data for traceability
• Reliable global shipping with stability-guaranteed packaging
• Dedicated technical support and optional custom synthesis service
• Demonstrates strong binding affinity to CRBN, VHL, or other E3 ligases
• Enables stable E3 ligase recruitment for targeted protein degradation
• Alkyne functional group enables click chemistry for efficient PROTAC assembly and bioconjugation applications.
• High specificity for CRBN E3 ligase targeting, making it optimal for the design of next-generation targeted protein degraders.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Related Product Recommendations
Please contact us with any specific requirements and we will get back to you as soon as possible.





